TROY, N.Y., March 30 /PRNewswire/ -- Evident Technologies introduced today
a second generation Type 2 EviTag(TM) luminescent label. The T2 EviTag has a
proprietary natural coating that provides increased flexibility, easier use,
wider applications and possible reduced testing costs in biological assays and
other types of life science research.
"At Evident, we are practical pioneers developing nanomaterials to meet
real needs and solve real problems," said Clint Ballinger, CEO of Evident
Technologies. "Our customers need smaller, brighter, more flexible fluorescing
markers to enable more applications across different life science market
segments. Our T2 EviTags meet these needs and reduce testing costs because of
their flexibility and adaptability. We see EviTags as an enabling technology
at the crossroads of nano and bio."
EviTags are biologically-inert, conjugation-ready fluorescent labels built
around a base of the company's EviDot(TM) quantum dots, which are
semiconductor nanocrystals coated with a variety of patented, water-
stabilizing surface treatments appropriate for a range of applications.
Type 1 EviTags feature robust and stable synthetic materials which help
withstand the rigors of testing. Evident's new Type 2 EviTags offer additional
benefits because of their natural surface coating, brighter fluorescence and
smaller size, which makes them more suitable for fluorescent resonance energy
transfer (FRET) work, live animal or in vivo imaging and molecular targeting.
"The work we are doing with Evident's tags is proving to be a first,
critical stage in further exploring the inner space of cells. Clearly, we
value these very bright probes as we hope to illuminate inner space," said Dr.
Carl Batt, Director Cornell University-Ludwig Institute for Cancer Research
Partnership, Liberty Hyde Bailey Professor of Cornell University.
Dr. Jonathan R. Slotkin, of The Brigham and Women's Hospital, Harvard
Medical School said, "It has been a pleasure working with Evident
Technologies' T2 EviTags in our preliminary studies labeling murine neural
progenitor cells for in vitro and in vivo experimentation. We have found the
T2 EviTags give robust fluorescent signal, and are remarkably stable in our
culture systems. "
"In addition, we have found Evident's scientific product development and
staff to be exceedingly knowledgeable, and we look forward to a continued
strong working relationship with them as we move further into the use of
quantum dots for in vivo transplantation experiments with neural progenitor
cells in both developmental and injury models," said Dr. Slotkin.
"With their new coatings, T2 EviTags have smaller hydrodynamic radii and
have been demonstrated to be efficient donors of energy transfer to acceptor
dyes. The use of quantum dots in these assays will reduce, if not resolve, the
laborious and time consuming data processing that is currently required to
correct the bleed-through contamination between donor and acceptor dyes,
making it easier and more straightforward to perform live-cell time-lapse FRET
to assay the highly dynamic and transient live cellular processes. Prior to
this, FRET has been hard to accomplish using traditional fluorophores to assay
dynamic events in live cells," said Dr. Margarida Barroso, Assistant Professor
at Albany Medical College.
Type 2 EviTags are available in seven colors from Lake Placid Blue (490nm)
to Maple Red-orange (620nm), with conjugation-ready surfaces of amine,
carboxyl and non-functionalized surfaces. Evident also has under development a
new class of EviTags capable of advanced deep tissue imaging, as illustrated.
These will be available for beta testing soon.
About Evident Technologies
Evident Technologies (http://www.evidenttech.com) is a pioneer in the
development of advanced nanomaterials engineered to enable the creation of
advanced products for numerous markets including life sciences, solid state
lighting, energy, security, telecommunications and emergent nanotechnology
markets. Evident works with customers worldwide to fashion these advanced
materials into new products and is also a leading commercial source for a wide
range of quantum dot material systems that offer advantages over traditional
semiconductors. For more information, visit http://www.evidenttech.com.
Caption: Type 2 EviTags as in vivo optical imaging agents using the dual
modality Kodak4000IS optical and X-ray imaging system.
About the image:
Human prostate cancer xenografts in nude scid mice were imaged with
EviTags under development using the Kodak4000IS dual modality imaging system.
The NIR optical image was co-registered with the X-ray image of tumor bearing
mice with and without EviTags. The strong signal attained with the EviTags
show the great potential for these reagents as in vivo optical imaging agents.
Image available at http://www.evidenttech.com/mouse
SOURCE Evident Technologies